Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice
- 249 Downloads
Associated with frank neuropathology, patients with Alzheimer’s disease suffer from a host of neuropsychiatric symptoms that include depression, apathy, agitation, and aggression. Negative allosteric modulators (NAMs) of α5-containing GABAA receptors have been suggested to be a novel target for antidepressant action. We hypothesized that pharmacological modulation of this target would engender increased motivation in stressful environments.
We utilized electrophysiological recordings from Xenopus oocytes and behavioral measures in mice to address this hypothesis.
In the forced-swim assay in mice that detects antidepressant drugs, the α5β3γ2 GABAΑ receptor NAM, RY-080 produced a marked antidepressant phenotype. Another compound, PWZ-029, was characterized as an α5β3γ2 receptor NAM of lower intrinsic efficacy in electrophysiological studies in Xenopus oocytes. In contrast to RY-080, PWZ-029 was only moderately active in the forced-swim assay and the α5β3γ2 receptor antagonist, Xli-093, was not active at all. The effects of RY-080 were prevented by the non-selective benzodiazepine receptor antagonist flumazenil as well as by the selective ligands, PWZ-029 and Xli-093. These findings demonstrate that this effect of RY-080 is driven by negative allosteric modulation of α5βγ2 GABAA receptors. RY-080 was not active in the tail-suspension test. We also demonstrated a reduction in the age-dependent hyperactivity exhibited by transgenic mice that accumulate pathological tau (rTg4510 mice) by RY-080. The decrease in hyperactivity by RY-080 was selective for the hyperactivity of the rTg4510 mice since the locomotion of control strains of mice were not significantly affected by RY-080.
α5βγ2 GABAA receptor NAMs might function as a pharmacological treatment for mood, amotivational syndromes, and psychomotor agitation in patients with Alzheimer’s and other neurodegenerative disorders.
KeywordsAlpha 5-containing GABAA receptors Antidepressant Tau-Depositing Mice Agitation rTg4510 mice
Bis[8-ethynyl-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid] 1,3-propanediyl ester hydrate
We thank the following granting agencies for support: MH-096463 and NS-076517, as well as the Austrian Science Fund (FWF I2306). We also acknowledge UW-Milwaukee’s Shimadzu Laboratory for Advanced and Applied Analytical Chemistry and support from the Milwaukee Institute of Drug Discovery and the University of Wisconsin Research Foundation.
We are grateful for Trace Murray of the Neuroscience Discovery Group of the Lilly Research Labs for her gracious help in obtaining the rTg4510 mice. We acknowledge excellent technical assistance by Raphael Holzinger.
Participated in research design: J. M. Witkin, S. D. Gleason, T. M. Jones, R. Cerne, M, Wakulchik, and M. Ernst.
Conducted experiments: JM Witkin, SD Gleason, M, Wakulchik, and M. Treven.
Contributed new reagents or analytic tools: K. R. Methuku2, R. Cerne, J.W. Cramer, T.M. Jones, M. M. Poe, G. Li, L. A. Arnold, J. M. Schkeryantz1, and J. M. Cook2.
Performed data analysis: JM Witkin, SD Gleason, R. Cern, M. Ernst, and M. Treven.
Wrote or contributed to the writing of the manuscript: All authors.
- Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR (2006b) L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology 51(6):1023–1029. https://doi.org/10.1016/j.neuropharm.2006.04.018 CrossRefPubMedGoogle Scholar
- Atack JR, Maubach KA, Wafford KA, O'Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NGB, McKernan RM, Murphy MG, Gingrich K, Dawson GR, Musson DG, Petty KJ (2009) In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J Pharmacol Exp Ther 331(2):470–484. https://doi.org/10.1124/jpet.109.157636 CrossRefPubMedGoogle Scholar
- Behlke LM, Foster RA, Liu J, Benke D, Benham RS, Nathanson AJ, Yee BK, Zeilhofer HU, Engin E, Rudolph U (2016) A pharmacogenetic ‘restriction-of-function’ approach reveals evidence for anxiolytic-like actions mediated by α5-containing gabaa receptors in mice. Neuropsychopharmacology 41(10):2492–2501. https://doi.org/10.1038/npp.2016.49 CrossRefPubMedPubMedCentralGoogle Scholar
- Carreno FR, Collins GT, Frazer A, Lodge DJ (2017) Selective pharmacological augmentation of hippocampal activity produces a sustained antidepressant-like response without abuse-related or psychotomimetic effects. Int J Neuropsychopharmacol 20(6):504–509. https://doi.org/10.1093/ijnp/pyx003 CrossRefPubMedPubMedCentralGoogle Scholar
- Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA, Cook JM (2015) A review of the updated pharmacophore for the alpha 5 GABA(a) benzodiazepine receptor model. Int J Med Chem 2015:1–54. https://doi.org/10.1155/2015/430248 Google Scholar
- Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Otu FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22(13):5572–5580PubMedGoogle Scholar
- Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM (2015) Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors. Neuropsychopharmacology 40(11):2499–2509. https://doi.org/10.1038/npp.2015.112 CrossRefPubMedPubMedCentralGoogle Scholar
- Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM (2009) Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J Pharmacol Exp Ther 329(2):429–438. https://doi.org/10.1124/jpet.108.143362 CrossRefPubMedGoogle Scholar
- Hajós M, Hoffmann WE, Orbán G, Kiss T, Erdi P (2004) Modulation of septo-hippocampal theta activity by GABAA receptors: an experimental and computational approach. Neuroscience 126(3):599–610. https://doi.org/10.1016/j.neuroscience.2004.03.043 CrossRefPubMedGoogle Scholar
- Liu CS, Ruthirakuhan M, Chau SA, Herrmann N, Carvalho AF, Lanctôt KL (2016) Pharmacological management of agitation and aggression in Alzheimer’s disease: a review of current and novel treatments. Curr Alzheimer Res 13(10):1134–1144. https://doi.org/10.2174/1567205013666160502122933 CrossRefPubMedGoogle Scholar
- Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R (2015) Alzheimer’s disease neuroimaging initiative. cognitive impairment precedes and predicts functional impairment in mild Alzheimer’s disease. J Alzheimers Dis 47:205–214CrossRefPubMedPubMedCentralGoogle Scholar
- Martínez-Cué C, Martínez P, Rueda N, Vidal R, García S, Vidal V, Corrales A, Montero JA, Pazos Á, Flórez J, Gasser R, Thomas AW, Honer M, Knoflach F, Trejo JL, Wettstein JG, Hernández MC (2013) Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome. J Neurosci 33(9):3953–3966. https://doi.org/10.1523/JNEUROSCI.1203-12.2013 CrossRefPubMedGoogle Scholar
- Matsumoto K, Puia G, Dong E, Pinna G (2007) GABAA receptor neurotransmission dysfunction in a mouse model of social isolation-induced stress: possible insights into a non-serotonergic mechanism of action of SSRIs in mood and anxiety disorders. Stress 10(1):3–12. https://doi.org/10.1080/10253890701200997 CrossRefPubMedGoogle Scholar
- Mendes-Silva AP, Pereira KS, Tolentino-Araujo GT, Nicolau Ede S, Silva-Ferreira CM, Teixeira AL, Diniz BS (2016) Shared biologic pathways between Alzheimer disease and major depression: a systematic review of microRNA expression studies. Am J Geriatr Psychiatry 24(10):903–912. https://doi.org/10.1016/j.jagp.2016.07.017 CrossRefPubMedGoogle Scholar
- Mirza NR, Larsen JS, Mathiasen C, Jacobsen TA, Munro G, Erichsen HK, Nielsen AN, Troelsen KB, Nielsen EO, Ahring PK (2008) NS11394 [3′-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J Pharmacol Exp Ther 327(3):954–968. https://doi.org/10.1124/jpet.108.138859 CrossRefPubMedGoogle Scholar
- Olsen RW, Sieghart W (2008) International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(a) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 60(3):243–260. https://doi.org/10.1124/pr.108.00505 CrossRefPubMedPubMedCentralGoogle Scholar
- Polc P, Bonetti EP, Schaffner R, Haefely W (1982) A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, β-carbolines, and phenobarbitone. Naunyn Schmiedeberg's Arch Pharmacol 321(4):260–264. https://doi.org/10.1007/BF00498510 CrossRefGoogle Scholar
- Quirk K, Blurton P, Fletcher S, Leeson P, Tang F, Mellilo D, Ragan CI, McKernan RM (1996) [3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit. Neuropharmacology 35(9-10):1331–1335. https://doi.org/10.1016/S0028-3908(96)00061-5 CrossRefPubMedGoogle Scholar
- Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25(46):10637–10647. https://doi.org/10.1523/JNEUROSCI.3279-05.2005 CrossRefPubMedGoogle Scholar
- Rudolph U, Möhler H (2014) GABAA receptor subtypes: therapeutic potential in down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol 54(1):483–507. https://doi.org/10.1146/annurev-pharmtox-011613-135947 CrossRefPubMedGoogle Scholar
- Savić MM, Clayton T, Furtmüller R, Gavrilović I, Samardzić J, Savić S, Huck S, Sieghart W, Cook JM (2008a) PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(a) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats. Brain Res 1208:150–159. https://doi.org/10.1016/j.brainres.2008.02.020 CrossRefPubMedPubMedCentralGoogle Scholar
- Savić MM, Huang S, Furtmüller R, Clayton T, Huck S, Obradović DI, Ugresić ND, Sieghart W, Bokonjić DR, Cook JM (2008b) Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology 33(2):332–339. https://doi.org/10.1038/sj.npp.1301403 CrossRefPubMedGoogle Scholar
- Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM (2011) Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7(3):280–292. https://doi.org/10.1016/j.jalz.2011.03.003 CrossRefPubMedPubMedCentralGoogle Scholar
- Towers SK, Gloveli T, Traub RD, Driver JE, Engel D, Fradley R, Rosahl TW, Maubach K, Buhl EH, Whittington MA (2004) Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol 559(3):721–728. https://doi.org/10.1113/jphysiol.2004.071191 CrossRefPubMedPubMedCentralGoogle Scholar
- Varagic Z, Wimmer L, Schnürch M, Mihovilovic MD, Huang S, Rallapalli S, Cook JM, Mirheydari P, Ecker GF, Sieghart W, Ernst M (2013) Identification of novel positive allosteric modulators and null modulators at the GABAA receptor α+β- interface. Br J Pharmacol 169(2):371–383. https://doi.org/10.1111/bph.12151 CrossRefPubMedPubMedCentralGoogle Scholar
- Zanos P, Nelson ME, Highland JN, Krimmel SR, Georgiou P, Gould TD, Thompson SM (2017) A Negative allosteric modulator for α5 subunit-containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice. eNeuro 4(1):0285–16.2017. https://doi.org/10.1523/ENEURO.0285-16.2017 CrossRefGoogle Scholar